New drugs are needed to shorten the duration of tuberculosis treatment. R207910, a diarylquinoline, is very active against Mycobacterium tuberculosis both in vitro and in mice. In healthy volunteers, co-administration of rifampin induced increased metabolism of R207910 resulting in a 50% reduction of exposure. We assessed the impact of reducing the dose of R207910 on efficacy when R207910 was combined with a background regimen of isoniazid, rifampin and pyrazinamide. Addition of 25 mg/kg or 12.5 mg/kg R207910 to the background regimen resulted in faster bacterial clearance and culture negativity. The difference in efficacy between the two doses was not statistically significant. The minimal bactericidal dose of R207910 when tested as combination was identical to that when tested in monotherapy.
INTRODUCTION
New antituberculosis drugs that have the potential to shorten the current duration of therapy for both active and latent tuberculosis, and to improve the efficacy of treatment regimens for multidrug-resistant TB (MDR-TB) are urgently needed. R207910 (TMC207 or J), a diarylquinoline, is a new compound exhibiting a new mode of action (inhibition of ATP synthase) against mycobacteria (1, 6 ).
The compound is being assessed in a phase IIb trial for the treatment of active tuberculosis in MDR-TB patients. In vitro, R207910 is active against sensitive and resistant strains of M. tuberculosis (1, 2) . In mice, it accelerates bacterial clearance when combined with regimens against both sensitive and MDRMycobacterium tuberculosis (1, 10) , Mycobacterium leprae (4) and Mycobacterium ulcerans (5) . In the established murine model of tuberculosis, monotherapy with R207910 is as active as the standard WHO regimen combining rifampin (RIF or R), isoniazid (INH or H) and pyrazinamide (PZA or Z), and when combined with RHZ or HZ or RZ, the lungs of mice became culture negative after just 2 months of treatment (1) .
When combined to pyrazinamide, R207910 acts synergically in the murine model (3) . In fact, the combination of R207910 and PZA lead to a complete eradication of the 7.2 log10 CFU, present in the lungs of mice at the onset of treatment, after only 2 months of treatment. Such level of efficacy needed 4 months of treatment with the triple-drug combination RIFmoxifloxacin-PZA (11).
In humans, an extended Early Bactericidal Assay (eEBA) was conducted in patients who were treated for seven days with R207910 given at
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on September 12, 2017 by guest http://aac.asm.org/ Downloaded from R207910 given at 400 mg per day showed a significant decrease in CFU counts in the sputum of treated patients in comparison with the pre-treatment levels (13).
A drug-drug interaction study was conducted in 16 healthy volunteers who received a single dose of 300 mg of R207910 alone and 7 daily doses of 10 mg/kg of RIF. The AUC 0-336h of R207910 after co-administration of RIF was about half when dosed alone, indicating that the metabolism of R207910 is induced by co-administration of RIF (unpublished data).
In the current study we aimed to determine the efficacy of different doses of R207910 in combination with RHZ in order to mimic the decrease of exposure to R207910 when combined to RIF. In addition, we wanted to measure the efficacy of R207910 and INH after one week of treatment, in order to compare it with the early bactericidal effect observed in patients. In experiments I and II, treatment was initiated 2 weeks after infection in order to mimic a large bacterial population as observed in human cavities, and was administered five days a week.
MATERIALS AND METHODS

Antimicrobial
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In In both experiments, solutions of R207910 and RIF were prepared in a 20% hydroxypropyl-β-cyclodextrin, those of PZA and INH were prepared in 10% hydroxypropyl-β-cyclodextrin and water, respectively, and were stored at 4°C. All the drugs were given orally by gavage.
The drugs were administered in the following dosages: 10, 25 and 150 mg/kg/day for RIF, INH and PZA, respectively. Based on AUC, these dosages, which are similar to those used in previous experiments (1, 8, 9, 10, 14) , were chosen as equipotent with the usual dosages administered to humans. Löwenstein-Jensen plates.
In both experiments, results of the cultures were recorded after incubation at 37°C for 4 weeks. The bactericidal effect of the treatment is defined as a significant decrease of the mean number of CFU in the treated group compared to pre-treatment value.
Statistical analysis. In experiments I and II, the Student t test was used to
analyze the spleen weights and CFU counts data. Since multiple comparisons were made, the Bonferroni correction of the p value was used. Since 6 and 5 CFU killing) when used in combination with RHZ was 12.5 mg/kg. This is in full agreement with the MBD of R207910 when used in monotherapy (1).
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That an identical MBD is obtained when R207910 is used in monotherapy and in combination with RHZ, suggests that a strong background regimen (RHZ) is not able to conceal the activity of even the lowest bactericidal dose of R207910. This is a surprising finding, as this was so far not observed with other new anti-TB drugs. When combined with RHZ during 8 weeks, PA-824 when used at its MBD of 100 mg/kg was not able to increase the bactericidal activity of the RHZ regimen (12). When moxifloxacin was given at 100 mg/kg 5 days a week for 8 weeks in combination with RHZ, the increase in bactericidal activity was modest (11). The addition of sparfloxacin to RHZ for 8 weeks did not improve the activity of RHZ (7). In conclusion, our study suggests that the addition of R207910 to the standard regimen RHZ remains an interesting option to study in clinical trials, despite the observed drug-drug interactions between rifampin and R207910. As a rapid rate of kill may or may not translate into a durable effect in patients, relapse rates obtained with reduced doses of R207910 should be studied in the mouse model. 
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